International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Boyle, 2008

Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74

Curado, 2007, Vol. IX

Travis, 2004

Travis, 1999

WHO, 1967

WHO, 1981

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Mitsudomi, 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol, 11, 121, 10.1016/S1470-2045(09)70364-X

Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530

Zhou, 2010, Efficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations, Ann Oncol, 21, viii1

Scagliotti, 2009, Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study, Eur J Cancer, 45, 2298, 10.1016/j.ejca.2009.04.033

Scagliotti, 2008, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer, J Clin Oncol, 26, 3543, 10.1200/JCO.2007.15.0375

Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5

Scagliotti, 2009, The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies, Oncologist, 14, 253, 10.1634/theoncologist.2008-0232

Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin, Oncol, 22, 2184

Cohen, 2007, FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer, Oncologist, 12, 713, 10.1634/theoncologist.12-6-713

Kodama, 2001, Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning, Lung Cancer, 33, 17, 10.1016/S0169-5002(01)00185-4

Suzuki, 2002, “Early” peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan, Ann Thorac Surg, 74, 1635, 10.1016/S0003-4975(02)03895-X

Takamochi, 2001, Pathologic N0 status in pulmonary adenocarcinoma is predictable by combining serum carcinoembryonic antigen level and computed tomographic findings, J Thorac Cardiovasc Surg, 122, 325, 10.1067/mtc.2001.114355

Sakurai, 2004, Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis, Am J Surg Pathol, 28, 198, 10.1097/00000478-200402000-00007

Adler, 1992, High-resolution CT of bronchioloalveolar carcinoma, AJR Am J Roentgenol, 159, 275, 10.2214/ajr.159.2.1321558

Aoki, 2001, Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival, Radiology, 220, 803, 10.1148/radiol.2203001701

El-Sherif, 2006, Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis, Ann Thorac Surg, 82, 408, 10.1016/j.athoracsur.2006.02.029

Nakamura, 2005, Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis, Br J Cancer, 92, 1033, 10.1038/sj.bjc.6602414

Okada, 2006, Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study, J Thorac Cardiovasc Surg, 132, 769, 10.1016/j.jtcvs.2006.02.063

Shah, 2006, The role of transbronchial fine needle aspiration in an integrated care pathway for the assessment of patients with suspected lung cancer, J Thorac Oncol, 1, 324, 10.1016/S1556-0864(15)31589-6

Edwards, 2000, Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category, J Clin Pathol, 53, 537, 10.1136/jcp.53.7.537

Cataluna, 1996, Cell type accuracy of bronchial biopsy specimens in primary lung cancer, Chest, 109, 1199, 10.1378/chest.109.5.1199

Travis, 2010, Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift, J Thorac Oncol, 5, 411, 10.1097/JTO.0b013e3181d57f6e

Schunemann, 2006, An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations, Am J Respir Crit Care Med, 174, 605, 10.1164/rccm.200602-197ST

Schunemann, 2008, GRADE: assessing the quality of evidence for diagnostic recommendations. ACP J, Club, 149, 2

Schunemann, 2008, Grading quality of evidence and strength of recommendations for diagnostic tests and strategies, BMJ, 336, 1106, 10.1136/bmj.39500.677199.AE

Guyatt, 2008, Going from evidence to recommendations, BMJ, 336, 1049, 10.1136/bmj.39493.646875.AE

Guyatt, 2008, What is “quality of evidence” and why is it important to clinicians?, BMJ, 336, 995, 10.1136/bmj.39490.551019.BE

Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD

Guyatt, 2010, GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables, J Clin Epidemiol

Loo, 2010, Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens, J Thorac Oncol, 5, 442, 10.1097/JTO.0b013e3181d40fac

Nicholson, 2010, Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis, J Thorac Oncol, 5, 436, 10.1097/JTO.0b013e3181c6ed9b

Barletta, 2009, Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma, J Cell Mol Med, 13, 1977, 10.1111/j.1582-4934.2008.00594.x

Deshpande, 2009, Grading of lung adenocarcinoma: architectural versus nuclear approach, Mod Pathol, 22, 1590

Sica, 2010, A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors, Am J Surg Pathol, 34, 1155, 10.1097/PAS.0b013e3181e4ee32

Yoshizawa, 2011, Prognostic significance of the proposed IASLC/ATS/ERS revised classification of lung adenocarcinoma in 514 stage I lung adenocarcinomas, Mod Pathol, 24

Thunnissen, 2010, Reproducibility of histopathological subtypes in pulmonary adenocarcinoma, Mod Pathol, 23, 415A

Noguchi, 1995, Small adenocarcinoma of the lung. Histologic characteristics and prognosis, Cancer, 75, 2844, 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#

Borczuk, 2009, Invasive size is an independent predictor of survival in pulmonary adenocarcinoma, Am J Surg Pathol, 33, 462, 10.1097/PAS.0b013e318190157c

Yim, 2007, Histologic features are important prognostic indicators in early stages lung adenocarcinomas, Mod Pathol, 20, 233, 10.1038/modpathol.3800734

Goldstein, 1999, Prognostic factors in T1 NO MO adenocarcinomas and bronchioloalveolar carcinomas of the lung, Am J Clin Pathol, 112, 391, 10.1093/ajcp/112.3.391

Clayton, 1986, Bronchioloalveolar carcinomas. Cell types, patterns of growth, and prognostic correlates, Cancer, 57, 1555, 10.1002/1097-0142(19860415)57:8<1555::AID-CNCR2820570820>3.0.CO;2-N

Daly, 1991, Bronchoalveolar carcinoma: factors affecting survival, Ann Thorac Surg, 51, 368, 10.1016/0003-4975(91)90847-J

Manning, 1984, Bronchioloalveolar carcinoma: the significance of two histopathologic types, Cancer, 54, 525, 10.1002/1097-0142(19840801)54:3<525::AID-CNCR2820540324>3.0.CO;2-X

Riquet, 2006, Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping, Ann Thorac Surg, 81, 1988, 10.1016/j.athoracsur.2006.01.021

Goldstein, 2001, Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies, Am J Clin Pathol, 116, 319, 10.1309/550P-QLJX-D84W-F6DN

Garfield, 2008, Bronchioloalveolar carcinoma: the case for two diseases, Clin Lung Cancer, 9, 24, 10.3816/CLC.2008.n.004

Garfield, 2009, The importance of distinguishing mucinous and nonmucinous bronchioloalveolar carcinomas, Lung, 187, 207, 10.1007/s00408-009-9149-3

Garfield, 2008, A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy, Cancer, 113, 1107, 10.1002/cncr.23662

Travis, 2005, Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma, J Clin Oncol, 23, 3279, 10.1200/JCO.2005.15.776

West, 2009, Bronchioloalveolar carcinoma: not as easy as “BAC.”, J Thorac Oncol, 4, 1047, 10.1097/JTO.0b013e3181b6ebda

Raz, 2006, Bronchioloalveolar carcinoma: a review, Clin Lung Cancer, 7, 313, 10.3816/CLC.2006.n.012

Gandara, 2006, Bronchioloalveolar carcinoma: the “changing face of lung cancer.”, Clin Lung Cancer, 7, 299

Watanabe, 2002, Results of wedge resection for focal bronchioloalveolar carcinoma showing pure ground-glass attenuation on computed tomography, Ann Thorac Surg, 73, 1071, 10.1016/S0003-4975(01)03623-2

Sakurai, 2004, Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment, Ann Thorac Surg, 78, 1728, 10.1016/j.athoracsur.2004.05.017

Vazquez, 2009, Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications, Lung Cancer, 64, 148, 10.1016/j.lungcan.2008.08.009

Yamato, 2001, Early results of a prospective study of limited resection for bronchioloalveolar adenocarcinoma of the lung, Ann Thorac Surg, 71, 971, 10.1016/S0003-4975(00)02507-8

Yamada, 2004, Video-assisted thoracic surgery for pure ground-glass opacities 2 cm or less in diameter, Ann Thorac Surg, 77, 1911, 10.1016/j.athoracsur.2003.12.040

Yoshida, 2005, Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience, J Thorac Cardiovasc Surg, 129, 991, 10.1016/j.jtcvs.2004.07.038

Koike, 2009, Limited resection for noninvasive bronchioloalveolar carcinoma diagnosed by intraoperative pathologic examination, Ann Thorac Surg, 88, 1106, 10.1016/j.athoracsur.2009.06.051

Motoi, 2008, Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis, Am J Surg Pathol, 32, 810, 10.1097/PAS.0b013e31815cb162

Carey, 1992, Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases, Thorax, 47, 1041, 10.1136/thx.47.12.1041

Weng, 1990, Multiple atypical adenomatous hyperplasia of type II pneumonocytes and bronchio-alveolar carcinoma, Histopathology, 16, 101, 10.1111/j.1365-2559.1990.tb01073.x

Nakanishi, 1990, Alveolar epithelial hyperplasia and adenocarcinoma of the lung, Arch Pathol Lab Med, 114, 363

Nakahara, 2001, Atypical adenomatous hyperplasia of the lung: a clinicopathological study of 118 cases including cases with multiple atypical adenomatous hyperplasia, Thorax, 56, 302, 10.1136/thorax.56.4.302

Miller, 1990, Bronchioloalveolar cell adenomas, Am J Surg Pathol, 14, 904, 10.1097/00000478-199010000-00002

Nakayama, 1990, Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content, Mod Pathol, 3, 314

Niho, 1999, Monoclonality of atypical adenomatous hyperplasia of the lung, Am J Pathol, 154, 249, 10.1016/S0002-9440(10)65271-6

Sakamoto, 2007, Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas, J Pathol, 212, 287, 10.1002/path.2165

Westra, 1996, K-ras oncogene activation in atypical alveolar hyperplasias of the human lung, Cancer Res, 56, 2224

Kohno, 2008, Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias, Carcinogenesis, 29, 957, 10.1093/carcin/bgn048

Yoshida, 2005, Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung, Lung Cancer, 50, 1, 10.1016/j.lungcan.2005.04.012

Kitamura, 1996, Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen, Am J Surg Pathol, 20, 553, 10.1097/00000478-199605000-00002

Takamochi, 2001, Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung, Am J Pathol, 159, 1941, 10.1016/S0002-9440(10)63041-6

Licchesi, 2008, Promoter hypermethylation of hallmark cancer genes in atypical adenomatous hyperplasia of the lung, Clin Cancer Res, 14, 2570, 10.1158/1078-0432.CCR-07-2033

Nakanishi, 2002, Expression of human telomerase RNA component and telomerase reverse transcriptase mRNA in atypical adenomatous hyperplasia of the lung, Hum Pathol, 33, 697, 10.1053/hupa.2002.125775

Seki, 2002, Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung, Clin Cancer Res, 8, 3046

Licchesi, 2008, Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung, Carcinogenesis, 29, 895, 10.1093/carcin/bgn017

Kerr, 2004, Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma, J Pathol, 203, 638, 10.1002/path.1557

Maeshima, 2010, Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence, J Thorac Oncol, 5, 466, 10.1097/JTO.0b013e3181ce3b73

Mori, 2001, Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung, Mod Pathol, 14, 72, 10.1038/modpathol.3880259

Kitamura, 1999, Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma, Am J Clin Pathol, 111, 610, 10.1093/ajcp/111.5.610

Koga, 2002, Lung adenocarcinoma with bronchioloalveolar carcinoma component is frequently associated with foci of high-grade atypical adenomatous hyperplasia, Am J Clin Pathol, 117, 464, 10.1309/CHXA-3MH0-B7FD-JGUL

Maeshima, 2010, Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator, J Thorac Oncol, 5, 333, 10.1097/JTO.0b013e3181c8cb95

Sawada, 2010, Localized mucinous bronchioloalveolar carcinoma of the lung: thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings, Jpn J Radiol, 28, 251, 10.1007/s11604-009-0414-4

Oka, 2010, Surgical resection for patients with mucinous bronchioloalveolar carcinoma, Asian J Surg, 33, 89, 10.1016/S1015-9584(10)60015-2

De Oliveira Duarte Achcar, 2009, Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile, Am J Clin Pathol, 131, 694, 10.1309/AJCPBS85VJEOBPDO

Nakamura, 2007, c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis, Cancer Sci, 98, 1006, 10.1111/j.1349-7006.2007.00493.x

Kim, 2004, Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung, Clin Cancer Res, 10, 7311, 10.1158/1078-0432.CCR-04-0811

Ding, 2008, Somatic mutations affect key pathways in lung adenocarcinoma, Nature, 455, 1069, 10.1038/nature07423

Shedden, 2008, Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study, Nat Med, 14, 822, 10.1038/nm.1790

Sholl, 2009, Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers, Cancer Res, 69, 8341, 10.1158/0008-5472.CAN-09-2477

Dacic, 2010, Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas, Mod Pathol, 23, 159, 10.1038/modpathol.2009.154

Girard, 2009, Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases, Am J Surg Pathol, 33, 1752, 10.1097/PAS.0b013e3181b8cf03

Lee, 2009, Lung adenocarcinoma as a solitary pulmonary nodule: prognostic determinants of CT, PET, and histopathologic findings, Lung Cancer, 66, 379, 10.1016/j.lungcan.2009.02.011

Yokose, 2000, Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter, Lung Cancer, 29, 179, 10.1016/S0169-5002(00)00103-3

Lin, 2006, Prognostic value of bronchioloalveolar carcinoma component in lung adenocarcinoma, Histol Histopathol, 21, 627

Okudela, 2010, Proposal of an improved histological sub-typing system for lung adenocarcinoma—significant prognostic values for stage I disease, Int J Clin Exp Pathol, 3, 348

Silver, 1997, True papillary carcinoma of the lung: a distinct clinicopathologic entity, Am J Surg Pathol, 21, 43, 10.1097/00000478-199701000-00005

Amin, 2002, Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance, Am J Surg Pathol, 26, 358, 10.1097/00000478-200203000-00010

Miyoshi, 2003, Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis, Am J Surg Pathol, 27, 101, 10.1097/00000478-200301000-00011

Kamiya, 2008, Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma, Mod Pathol, 21, 992, 10.1038/modpathol.2008.79

Kawakami, 2007, Micropapillary pattern and grade of stromal invasion in pT1 adenocarcinoma of the lung: usefulness as prognostic factors, Mod Pathol, 20, 514, 10.1038/modpathol.3800765

Kuroda, 2006, Lung adenocarcinoma with a micropapillary pattern: a clinicopathological study of 25 cases, APMIS, 114, 381, 10.1111/j.1600-0463.2006.apm_340.x

Kuroda, 2005, Pulmonary adenocarcinoma with micropapillary component: an immunohistochemical study. Case report, APMIS, 113, 550, 10.1111/j.1600-0463.2005.apm_151.x

Maeda, 2009, Lung adenocarcinomas with micropapillary components, Gen Thorac Cardiovasc Surg, 57, 534, 10.1007/s11748-009-0436-y

Makimoto, 2005, Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (</=20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours), Histopathology, 46, 677, 10.1111/j.1365-2559.2005.02126.x

Miyoshi, 2005, Possible mechanism of metastasis in lung adenocarcinomas with a micropapillary pattern, Pathol Int, 55, 419, 10.1111/j.1440-1827.2005.01847.x

Roh, 2004, Relationship between micropapillary component and micrometastasis in the regional lymph nodes of patients with stage I lung adenocarcinoma, Histopathology, 45, 580, 10.1111/j.1365-2559.2004.01953.x

Sanchez-Mora, 2008, Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series, Hum Pathol, 39, 324, 10.1016/j.humpath.2007.05.029

Tsutsumida, 2007, A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis, Mod Pathol, 20, 638, 10.1038/modpathol.3800780

Wislez, 2010, Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib, Lung Cancer, 68, 185, 10.1016/j.lungcan.2009.05.021

Hata, 2010, Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma, J Thorac Oncol, 5, 1197, 10.1097/JTO.0b013e3181e2a2bc

Lee, 2009, Mucinous versus nonmucinous solitary pulmonary nodular bronchioloalveolar carcinoma: CT and FDG PET findings and pathologic comparisons, Lung Cancer, 65, 170, 10.1016/j.lungcan.2008.11.009

Miyake, 1995, Mucin-producing tumor of the lung: CT findings, J Thorac Imaging, 10, 96, 10.1097/00005382-199521000-00003

Casali, 2010, A single institution-based retrospective study of surgically treated bronchioloalveolar adenocarcinoma of the lung: clinicopathologic analysis, molecular features, and possible pitfalls in routine practice, J Thorac Oncol, 5, 830, 10.1097/JTO.0b013e3181d60ff5

Akira, 1999, High-resolution CT findings of diffuse bronchioloalveolar carcinoma in 38 patients, AJR Am J Roentgenol, 173, 1623, 10.2214/ajr.173.6.10584811

Kodama, 2002, Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years, Ann Thorac Surg, 73, 386, 10.1016/S0003-4975(01)03410-5

Nagao, 2002, Measurement of localized ground-glass attenuation on thin-section computed tomography images: correlation with the progression of bronchioloalveolar carcinoma of the lung, Invest Radiol, 37, 692, 10.1097/00004424-200212000-00009

Saito, 2009, Initial findings and progression of lung adenocarcinoma on serial computed tomography scans, J Comput Assist Tomogr, 33, 42, 10.1097/RCT.0b013e3181633509

Yabuuchi, 2000, High-resolution CT characteristics of poorly differentiated adenocarcinoma of the peripheral lung: comparison with well differentiated adenocarcinoma, Radiat Med, 18, 343

Im, 1990, Lobar bronchioloalveolar carcinoma: ‘Angiogram sign’ on CT scans, Radiology, 176, 749, 10.1148/radiology.176.3.2167502

Tateishi, 2005, Mucin-producing adenocarcinoma of the lung: thin-section computed tomography findings in 48 patients and their effect on prognosis, J Comput Assist Tomogr, 29, 361, 10.1097/01.rct.0000162820.08909.e1

Shah, 2002, Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma, Hum Pathol, 33, 915, 10.1053/hupa.2002.126876

Finberg, 2007, Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features, J Mol Diagn, 9, 320, 10.2353/jmoldx.2007.060182

Sakuma, 2007, Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations, Am J Clin Pathol, 128, 100, 10.1309/WVXFGAFLAUX48DU6

Marchetti, 1996, Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype, J Pathol, 179, 254, 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J

Maeshima, 2002, Mixed mucinous-type and non-mucinous-type adenocarcinoma of the lung: immunohistochemical examination and K-ras gene mutation, Virchows Arch, 440, 598, 10.1007/s00428-002-0629-6

Tam, 2006, Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features, Clin Cancer Res, 12, 1647, 10.1158/1078-0432.CCR-05-1981

Copin, 2001, Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas, HumPathol, 32, 274

Awaya, 2004, Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung, Am J Clin Pathol, 121, 644, 10.1309/U4WGE9EBFJN6CM8R

Sato, 2006, Bronchioloalveolar carcinoma of mixed mucinous and nonmucinous type: immunohistochemical studies and mutation analysis of the p53 gene, Pathol Res Pract, 202, 751, 10.1016/j.prp.2006.07.002

Tsuta, 2006, Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin, J Pathol, 209, 78, 10.1002/path.1947

Sica, 2008, Reassessment of the histologic spectrum of mucinous bronchioloalveolar carcinoma (mBAC), Mod Pathol, 21, 351A

Gaeta, 1999, Mucinous cystadenocarcinoma of the lung: CT-pathologic correlation in three cases, J Comput Assist Tomogr, 23, 641, 10.1097/00004728-199907000-00028

Deshpande, 2009, Clear cell change in lung adenocarcinoma: a cytologic change rather than a histologic variant, Mod Pathol, 22, 1595

Cohen, 2010, Signet ring cell features (SRCF) in lung adenocarcinoma: a cytologic feature or a histologic subtype?, Mod Pathol, 23, 404A

Rodig, 2009, Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population, Clin Cancer Res, 15, 5216, 10.1158/1078-0432.CCR-09-0802

Inamura, 2005, Pulmonary adenocarcinomas with enteric differentiation: histologic and immunohistochemical characteristics compared with metastatic colorectal cancers and usual pulmonary adenocarcinomas, Am J Surg Pathol, 29, 660, 10.1097/01.pas.0000160438.00652.8b

Moran, 1992, Mucinous (so-called colloid) carcinomas of lung, Mod Pathol, 5, 634

Rossi, 2004, Primary mucinous (so-called colloid) carcinomas of the lung: a clinicopathologic and immunohistochemical study with special reference to CDX-2 homeobox gene and MUC2 expression, Am J Surg Pathol, 28, 442, 10.1097/00000478-200404000-00003

Gao, 2005, The spectrum of pulmonary mucinous cystic neoplasia: a clinicopathologic and immunohistochemical study of ten cases and review of literature, Am J Clin Pathol, 124, 62, 10.1309/52XXR6E6U0J2JX0F

Nakatani, 1998, Pulmonary adenocarcinomas of the fetal lung type: a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms, Am J Surg Pathol, 22, 399, 10.1097/00000478-199804000-00003

Nakatani, 2002, Aberrant nuclear localization and gene mutation of beta-catenin in low-grade adenocarcinoma of fetal lung type: up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules, Mod Pathol, 15, 617, 10.1038/modpathol.3880575

Sekine, 2003, Beta-catenin mutations in pulmonary blastomas: association with morule formation, J Pathol, 200, 214, 10.1002/path.1352

Li, 2009, Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma: case report and review of literature, Am J Clin Pathol, 131, 129, 10.1309/AJCPB04XWICTFERL

Hatanaka K, Tsuta K, Watanabe K, et al. Primary pulmonary adenocarcinoma with enteric differentiation resembling metastatic colorectal carcinoma: a report of the second case negative for cytokeratin 7. Pathol Res Pract. In press.

Yousem, 2005, Pulmonary intestinal-type adenocarcinoma does not show enteric differentiation by immunohistochemical study, Mod Pathol, 18, 816, 10.1038/modpathol.3800358

Rossi, 2009, A reevaluation of the clinical significance of histological subtyping of non–small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments, Int J Surg Pathol, 17, 206, 10.1177/1066896909336178

Rossi, 2009, Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer, J Clin Oncol, 27, e141, 10.1200/JCO.2009.24.0515

Suh, 2011, Testing of new IASLC/ATS/ERS criteria for diagnosis of lung adenocarcinoma (AD) in small biopsies: minimize immunohistochemistry (IHC) to maximize tissue for molecular studies, Mod Pathol, 24

Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163

Yatabe, 2002, TTF-1 expression in pulmonary adenocarcinomas, Am J Surg Pathol, 26, 767, 10.1097/00000478-200206000-00010

Lau, 2002, Thyroid transcription factor-1: a review, Appl Immunohistochem Mol Morphol, 10, 97, 10.1097/00129039-200206000-00001

Camilo, 2006, Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas, Hum Pathol, 37, 542, 10.1016/j.humpath.2005.12.019

Wu, 2003, p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung, Am J Clin Pathol, 119, 696, 10.1309/P5ABR5KQ89RNJTFH

Chu, 2002, Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases, Mod Pathol, 15, 6, 10.1038/modpathol.3880483

Ordonez, 2000, Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma, Am J Surg Pathol, 24, 598, 10.1097/00000478-200004000-00016

Kaufmann, 2000, Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B, Histopathology, 36, 8, 10.1046/j.1365-2559.2000.00801.x

Kargi, 2007, The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas, Appl Immunohistochem Mol Morphol, 15, 415, 10.1097/PAI.0b013e31802fab75

Khayyata, 2009, Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens, Diagn Cytopathol, 37, 178, 10.1002/dc.20975

Chu, 2000, Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases, Mod Pathol, 13, 962, 10.1038/modpathol.3880175

Rivera, 2007, Initial diagnosis of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 132, 131S, 10.1378/chest.07-1357

Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. In press.

Sigel, 2010, Subtyping of non-small cell lung carcinoma (NSCLC): comparison of cytology and small biopsy specimens, Mod Pathol, 23, 414A

Zhang, 2008, Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer, Lung Cancer, 60, 175, 10.1016/j.lungcan.2007.10.011

Zakowski, 2009, Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib, Arch Pathol Lab Med, 133, 470, 10.5858/133.3.470

Wu, 2008, Frequent EGFR mutations in malignant pleural effusion of lung adenocarcinoma, Eur Respir J, 32, 924, 10.1183/09031936.00167407

Au, 2004, P63 expression in lung carcinoma: a tissue microarray study of 408 cases, Appl Immunohistochem Mol Morphol, 12, 240, 10.1097/00129039-200409000-00010

Ang, 2010, Expression of squamous markers in lung adenocarcinoma (AD): clinicopathologic and molecular correlates, and implications for differentiation from squamous cell carcinoma (SqCC), Mod Pathol, 23, 397A

Ionescu, 2007, Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance, Am J Surg Pathol, 31, 26, 10.1097/01.pas.0000213319.04919.97

Sterlacci, 2009, Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases, Virchows Arch, 455, 125, 10.1007/s00428-009-0812-0

Chung, 1982, Carcinoma of the lung: evaluation of histological grade and factors influencing prognosis, Ann Thorac Surg, 33, 599, 10.1016/S0003-4975(10)60819-3

Kobayashi, 2007, Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less, J Thorac Oncol, 2, 808, 10.1097/JTO.0b013e31814617c7

Nakazato, 2009, Nuclear grading of primary pulmonary adenocarcinomas—correlation between nuclear size and prognosis, J Thorac Oncol, 4, S495

Petersen, 2009, Core classification of lung cancer: correlating nuclear size and mitoses with ploidy and clinicopathological parameters, Lung Cancer, 65, 312, 10.1016/j.lungcan.2008.12.013

Aida, 2004, Prognostic analysis of pulmonary adenocarcinoma subclassification with special consideration of papillary and bronchioloalveolar types, Histopathology, 45, 468, 10.1111/j.1365-2559.2004.01946.x

Gleason, 1992, Histologic grading of prostate cancer: a perspective, Hum Pathol, 23, 273, 10.1016/0046-8177(92)90108-F

Kadota, 2011, Nuclear grading system predicts recurrence in stage I lung adenocarcinoma patients, Mod Pathol, 24

Li, 2008, EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression, J Mol Diagn, 10, 242, 10.2353/jmoldx.2008.070178

Lim, 2009, Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC), J Thorac Oncol, 4, 12, 10.1097/JTO.0b013e3181913e28

Savic, 2008, Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers, Br J Cancer, 98, 154, 10.1038/sj.bjc.6604142

Miller, 2008, Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib, J Clin Oncol, 26, 1472, 10.1200/JCO.2007.13.0062

Kimura, 2006, EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib, Br J Cancer, 95, 1390, 10.1038/sj.bjc.6603428

Borczuk, 2004, Molecular signatures in biopsy specimens of lung cancer, Am J Respir Crit Care Med, 170, 167, 10.1164/rccm.200401-066OC

Zudaire, 2008, Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates, Histol Histopathol, 23, 33

Gordon, 2003, A prognostic test for adenocarcinoma of the lung from gene expression profiling data, Cancer Epidemiol Biomarkers Prev, 12, 905

Solomon, 2010, Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis, AJR Am J Roentgenol, 194, 266, 10.2214/AJR.09.2858

Asano, 2006, Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay, Clin Cancer Res, 12, 43, 10.1158/1078-0432.CCR-05-0934

Otani, 2008, Detection of EGFR gene mutations using the wash fluid of CT-guided biopsy needle in NSCLC patients, J Thorac Oncol, 3, 472, 10.1097/JTO.0b013e31816de2cd

Bepler, 2006, RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer, J Clin Oncol, 24, 4731, 10.1200/JCO.2006.06.1101

Olaussen, 2006, DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy, N Engl J Med, 355, 983, 10.1056/NEJMoa060570

Chang, 2010, The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer, Lung Cancer, 69, 323, 10.1016/j.lungcan.2009.12.002

Monica, 2009, Differential thymidylate synthase expression in different variants of large-cell carcinoma of the lung, Clin Cancer Res, 15, 7547, 10.1158/1078-0432.CCR-09-1641

Kang, 2010, The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection, Lung Cancer, 68, 478, 10.1016/j.lungcan.2009.07.004

Rosell, 2009, Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS, One, 4, e5133, 10.1371/journal.pone.0005133

Savci-Heijink, 2009, The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung, Am J Pathol, 174, 1629, 10.2353/ajpath.2009.080778

Monica, 2009, Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung, Mod Pathol, 22, 709, 10.1038/modpathol.2009.30

Bishop, 2010, Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma, Hum Pathol, 41, 20, 10.1016/j.humpath.2009.06.014

Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314

Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938

Pao, 2004, EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci USA, 101, 13306, 10.1073/pnas.0405220101

Azzoli, 2009, American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer, J Clin Oncol, 27, 6251, 10.1200/JCO.2009.23.5622

Pao, 2009, Integration of molecular profiling into the lung cancer clinic, Clin Cancer Res, 15, 5317, 10.1158/1078-0432.CCR-09-0913

Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993

Detterbeck, 2007, Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 132, 202S, 10.1378/chest.07-1362

Schrump, 2008, Non-small cell lung cancer, 887

Sculier, 2008, The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition, J Thorac Oncol, 3, 457, 10.1097/JTO.0b013e31816de2b8

Chansky, 2009, The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer, J Thorac Oncol, 4, 792, 10.1097/JTO.0b013e3181a7716e

Janjigian, 2010, Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV Nonsmall cell lung cancer, Cancer, 116, 670, 10.1002/cncr.24813

Miller, 2004, Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer, J Clin Oncol, 22, 1103, 10.1200/JCO.2004.08.158

West, 2006, Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126, J Clin Oncol, 24, 1807, 10.1200/JCO.2005.04.9890

Sequist, 2007, Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer, J Clin Oncol, 25, 587, 10.1200/JCO.2006.07.3585

Sutani, 2006, Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp, Br J Cancer, 95, 1483, 10.1038/sj.bjc.6603466

Inoue, 2006, Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations, J Clin Oncol, 24, 3340, 10.1200/JCO.2005.05.4692

Inoue, 2009, First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy, J Clin Oncol, 27, 1394, 10.1200/JCO.2008.18.7658

Tamura, 2008, Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403), Br J Cancer, 98, 907, 10.1038/sj.bjc.6604249

Yoshida, 2007, Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer, J Thorac Oncol, 2, 22, 10.1016/S1556-0864(15)30013-7

Douillard, 2010, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial, J Clin Oncol, 28, 744, 10.1200/JCO.2009.24.3030

Hirsch, 2006, Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer, J Clin Oncol, 24, 5034, 10.1200/JCO.2006.06.3958

Zhu, 2008, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR. 21, J Clin Oncol, 26, 4268, 10.1200/JCO.2007.14.8924

Sholl, 2010, EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry, Am J Clin Pathol, 133, 922, 10.1309/AJCPST1CTHZS3PSZ

Kawahara, 2010, Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation specific antibodies for immunohistochemical analysis, Clin Cancer Res, 16, 3163, 10.1158/1078-0432.CCR-09-3239

Brevet, 2010, Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR, J Mol Diagn, 12, 169, 10.2353/jmoldx.2010.090140

Yu, 2009, Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer, Clin Cancer Res, 15, 3023, 10.1158/1078-0432.CCR-08-2739

Fukuoka, 2009, Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboblatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small-cell lung cancer (NSCLC) in Asia (IPASS), J Clin Oncol, 27, 521S, 10.1200/jco.2009.27.15_suppl.8006

Kubota, 2009, Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study, J Thorac Oncol, 4, 1530, 10.1097/JTO.0b013e3181b9e608

Zinner, 2010, Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials, Clin Lung Cancer, 11, 126, 10.3816/CLC.2010.n.017

Gronberg, 2009, Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer, J Clin Oncol, 27, 3217, 10.1200/JCO.2008.20.9114

Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884

Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945

Wong, 2009, The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer, 115, 1723, 10.1002/cncr.24181

Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448

Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N Engl J Med, 363, 1734, 10.1056/NEJMoa1007478

Mao, 2010, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies, Lung Cancer, 69, 272, 10.1016/j.lungcan.2009.11.020

Linardou, 2008, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, Lancet Oncol, 9, 962, 10.1016/S1470-2045(08)70206-7

Goldstraw, 2009

Goldstraw, 2007, The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac, Oncol, 2, 706

Pignon, 2008, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, J Clin Oncol, 26, 3552, 10.1200/JCO.2007.13.9030

Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017

Kim, 2005, Identification of bronchioalveolar stem cells in normal lung and lung cancer, Cell, 121, 823, 10.1016/j.cell.2005.03.032

Weir, 2007, Characterizing the cancer genome in lung adenocarcinoma, Nature, 450, 893, 10.1038/nature06358

Tanaka, 2007, Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1, Cancer Res, 67, 6007, 10.1158/0008-5472.CAN-06-4774

Colby, 2007, Lungs, 473

Wang, 2002, P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors, Hum Pathol, 33, 921, 10.1053/hupa.2002.126878

Takeuchi, 2006, Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors, J Clin Oncol, 24, 1679, 10.1200/JCO.2005.03.8224

Colby, 1998, Precursors to pulmonary neoplasia, Adv Anat Pathol, 5, 205, 10.1097/00125480-199807000-00001

Westra, 2000, Early glandular neoplasia of the lung, Respir Res, 1, 163, 10.1186/rr28

Tang, 2008, Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas, Cancer Prev Res (Phila Pa), 1, 192, 10.1158/1940-6207.CAPR-08-0032

Tang, 2005, EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients, Cancer Res, 65, 7568, 10.1158/0008-5472.CAN-05-1705

Soh, 2008, Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung, J Thorac Oncol, 3, 340, 10.1097/JTO.0b013e318168d20a

Yatabe, 2008, Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer, Cancer Res, 68, 2106, 10.1158/0008-5472.CAN-07-5211

Tang, 2007, Derivation of stable microarray cancer-differentiating signatures using consensus scoring of multiple random sampling and gene-ranking consistency evaluation, Cancer Res, 67, 9996, 10.1158/0008-5472.CAN-07-1601

Koga, 2001, Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma, Clin Cancer Res, 7, 1730

Marchetti, 1998, FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations, J Pathol, 184, 240, 10.1002/(SICI)1096-9896(199803)184:3<240::AID-PATH20>3.0.CO;2-B

Yoshida, 2007, Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity, Jpn J Clin Oncol, 37, 907, 10.1093/jjco/hym139

Terasaki, 2003, Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization, Am J Surg Pathol, 27, 937, 10.1097/00000478-200307000-00009

Huang, 1998, Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer, Int J Oncol, 12, 553

Shigematsu, 2005, Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers, J Natl Cancer Inst, 97, 339, 10.1093/jnci/dji055

Marchetti, 2005, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment, J Clin Oncol, 23, 857, 10.1200/JCO.2005.08.043

Ohtsuka, 2006, A clinicopathological study of resected pulmonary nodules with focal pure ground-glass opacity, Eur J Cardiothorac Surg, 30, 160, 10.1016/j.ejcts.2006.03.058

Bryant, 2010, Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study, PLoS One, 5, e11712, 10.1371/journal.pone.0011712

Yousem, 2008, The histopathology of BRAF-V600E-mutated lung adenocarcinoma, Am J Surg Pathol, 32, 1317, 10.1097/PAS.0b013e31816597ca

Conde, 2006, Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling, Clin Cancer Res, 12, 710, 10.1158/1078-0432.CCR-05-1362

Hirsch, 2005, Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a southwest oncology group study, J Clin Oncol, 23, 6838, 10.1200/JCO.2005.01.2823

Tanaka, 2009, Magnetic resonance imaging in peripheral lung adenocarcinoma: correlation with histopathologic features, J Thorac Imaging, 24, 4, 10.1097/RTI.0b013e31818703b7

Kim, 2008, Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung, Lung Cancer, 59, 111, 10.1016/j.lungcan.2007.08.008

Ang, 2010, Characteristic morphology and immunoprofile of lung adenocarcinoma with KRAS mutations: propensity for solid growth pattern and correlation with TTF-1 expression, Mod Pathol, 23, 396A

Saad, 2004, Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma, Am J Clin Pathol, 122, 421, 10.1309/UMF715KRG2V198YD

Sasaki, 2006, Uncommon V599E BRAF mutations in Japanese patients with lung cancer, J Surg Res, 133, 203, 10.1016/j.jss.2005.10.022

Naoki, 2002, Missense mutations of the BRAF gene in human lung adenocarcinoma, Cancer Res, 62, 7001

Tang, 2008, Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer, Br J Cancer, 99, 911, 10.1038/sj.bjc.6604559

Cappuzzo, 2009, MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients, Ann Oncol, 20, 298, 10.1093/annonc/mdn635

Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478

Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, e73, 10.1371/journal.pmed.0020073

Sequist, 2008, First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations, J Clin Oncol, 26, 2442, 10.1200/JCO.2007.14.8494

Nguyen, 2009, Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway, Clin Lung Cancer, 10, 281, 10.3816/CLC.2009.n.039

Takahashi, 2010, Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene, Ann Surg Oncol, 17, 889, 10.1245/s10434-009-0808-7

Inamura, 2009, EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset, Mod Pathol, 22, 508, 10.1038/modpathol.2009.2

Takeuchi, 2009, KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer, Clin Cancer Res, 15, 3143, 10.1158/1078-0432.CCR-08-3248

Yoshida A, Tsuta K, Watanabe SI, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer. In press.

Jokoji, 2010, Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma, J Clin Pathol, 63, 1066, 10.1136/jcp.2010.081166

Inamura, 2008, EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers, J Thorac Oncol, 3, 13, 10.1097/JTO.0b013e31815e8b60

Mino-Kenudson, 2010, A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry, Clin Cancer Res, 16, 1561, 10.1158/1078-0432.CCR-09-2845

Sakairi, 2010, EML4-ALK fusion gene assessment using metastatic lymph node samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration, Clin Cancer Res, 16, 4938, 10.1158/1078-0432.CCR-10-0099

Boland, 2009, Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas, Hum Pathol, 40, 1152, 10.1016/j.humpath.2009.01.012

Beer, 2002, Gene-expression profiles predict survival of patients with lung adenocarcinoma, Nat Med, 8, 816, 10.1038/nm733

Borczuk, 2005, Lung adenocarcinoma global profiling identifies type II transforming growth factor-(beta) receptor as a repressor of invasiveness, Am J Respir Crit Care Med, 172, 729, 10.1164/rccm.200504-615OC

Shibata, 2007, Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma, Cancer Sci, 98, 985, 10.1111/j.1349-7006.2007.00483.x

Berrar, 2005, Survival trees for analyzing clinical outcome in lung adenocarcinomas based on gene expression profiles: identification of neogenin and diacylglycerol kinase alpha expression as critical factors, J Comput Biol, 12, 534, 10.1089/cmb.2005.12.534

Bianchi, 2007, Survival prediction of stage I lung adenocarcinomas by expression of 10 genes, J Clin Invest, 117, 3436, 10.1172/JCI32007

Endoh, 2004, Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction, J Clin Oncol, 22, 811, 10.1200/JCO.2004.04.109

Guo, 2006, Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma, Clin Cancer Res, 12, 3344, 10.1158/1078-0432.CCR-05-2336

Hayes, 2006, Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts, J Clin Oncol, 24, 5079, 10.1200/JCO.2005.05.1748

Inamura, 2007, A metastatic signature in entire lung adenocarcinomas irrespective of morphological heterogeneity, Hum Pathol, 38, 702, 10.1016/j.humpath.2006.11.019

Larsen, 2007, Gene expression signature predicts recurrence in lung adenocarcinoma, Clin Cancer Res, 13, 2946, 10.1158/1078-0432.CCR-06-2525

Liu, 2006, Predicting survival within the lung cancer histopathological hierarchy using a multi-scale genomic model of development, PLoS Med, 3, e232, 10.1371/journal.pmed.0030232

Sun, 2008, Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival, J Clin Oncol, 26, 877, 10.1200/JCO.2007.13.1516

Xi, 2005, Prediction of lymph node metastasis by analysis of gene expression profiles in primary lung adenocarcinomas, Clin Cancer Res, 11, 4128, 10.1158/1078-0432.CCR-04-2525

Potti, 2006, A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer, N Engl J Med, 355, 570, 10.1056/NEJMoa060467

Chen, 2007, A five-gene signature and clinical outcome in non-small-cell lung cancer, N Engl J Med, 356, 11, 10.1056/NEJMoa060096

Chitale, 2009, An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors, Oncogene, 28, 2773, 10.1038/onc.2009.135

Tonon, 2005, Common and contrasting genomic profiles among the major human lung cancer subtypes, Cold Spring Harb Symp Quant Biol, 70, 11, 10.1101/sqb.2005.70.021

Aviel-Ronen, 2008, Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features, Proc Natl Acad Sci USA, 105, 10155, 10.1073/pnas.0709618105

Chang, 2008, Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients, Lung Cancer, 61, 328, 10.1016/j.lungcan.2008.01.009

Cappuzzo, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, J Natl Cancer Inst, 97, 643, 10.1093/jnci/dji112

Dacic, 2005, Patterns of allelic loss of synchronous adenocarcinomas of the lung, Am J Surg Pathol, 29, 897, 10.1097/01.pas.0000164367.96379.66

Wang, 2009, Evidence for common clonal origin of multifocal lung cancers, J Natl Cancer Inst, 101, 560, 10.1093/jnci/djp054

Girard, 2009, Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers, Clin Cancer Res, 15, 5184, 10.1158/1078-0432.CCR-09-0594

van Rens, 2002, p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma, Cancer, 94, 188, 10.1002/cncr.10001

Matsuzoe, 1999, Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation, Br J Cancer, 79, 1549, 10.1038/sj.bjc.6690247

Wang, 1999, Carcinogen exposure, p53 alteration, and K-ras mutation in synchronous multiple primary lung carcinoma, Cancer, 85, 1734, 10.1002/(SICI)1097-0142(19990415)85:8<1734::AID-CNCR13>3.0.CO;2-1

Lau, 1997, Clonal origin of multiple lung cancers: K-ras and p53 mutations determined by nonradioisotopic single-strand conformation polymorphism analysis, Diagn Mol Pathol, 6, 179, 10.1097/00019606-199708000-00001

Girard, 2010, Use of epidermal growth factor receptor/Kirsten rat sarcoma2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines, Chest, 137, 46, 10.1378/chest.09-0325

Nonami, 2003, Study of the diagnostic difference between the clinical diagnostic criteria and results of immunohistochemical staining of multiple primary lung cancers, J Cardiovasc Surg (Torino), 44, 661

Vansteenkiste, 2001, Practical approach to patients presenting with multiple synchronous suspect lung lesions: a reflection on the current TNM classification based on 54 cases with complete follow-up, Lung Cancer, 34, 169, 10.1016/S0169-5002(01)00245-8

Yoshino, 1997, Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis, Ann Thorac Surg, 64, 809, 10.1016/S0003-4975(97)00281-6

Chung, 2009, Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread, J Thorac Oncol, 4, 1490, 10.1097/JTO.0b013e3181bc9731

Balak, 2006, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors, Clin Cancer Res, 12, 6494, 10.1158/1078-0432.CCR-06-1570

Jackman, 2006, Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib, J Clin Oncol, 24, 4517, 10.1200/JCO.2006.06.6126

Schmid, 2009, EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases, Clin Cancer Res, 15, 4554, 10.1158/1078-0432.CCR-09-0089

Monaco, 2010, A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases, Hum Pathol, 41, 94, 10.1016/j.humpath.2009.06.019

Meert, 2002, The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis, Eur Respir J, 20, 975, 10.1183/09031936.02.00296502

Berghmans, 2006, Thyroid transcription factor 1—a new prognostic factor in lung cancer: a meta-analysis, Ann Oncol, 17, 1673, 10.1093/annonc/mdl287

Mascaux, 2005, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis, Br J Cancer, 92, 131, 10.1038/sj.bjc.6602258

Nakamura, 2005, Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis, Cancer, 103, 1865, 10.1002/cncr.20957

Mitsudomi, 2000, Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis, Clin Cancer Res, 6, 4055

Steels, 2001, Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis, Eur Respir J, 18, 705, 10.1183/09031936.01.00062201

Martin, 2004, Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis, Br J Cancer, 91, 2018, 10.1038/sj.bjc.6602233

Martin, 2003, Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis, Br J Cancer, 89, 55, 10.1038/sj.bjc.6601095

Mascaux, 2006, Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results, Br J Cancer, 95, 139, 10.1038/sj.bjc.6603226

Marks, 2008, Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma, J Thorac Oncol, 3, 111, 10.1097/JTO.0b013e318160c607

Kosaka, 2009, Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma, J Thorac Oncol, 4, 22, 10.1097/JTO.0b013e3181914111

Yanaihara, 2006, Unique microRNA molecular profiles in lung cancer diagnosis and prognosis, Cancer Cell, 9, 189, 10.1016/j.ccr.2006.01.025

Raponi, 2009, MicroRNA classifiers for predicting prognosis of squamous cell lung cancer, Cancer Res, 69, 5776, 10.1158/0008-5472.CAN-09-0587

Hansell, 2008, Fleischner Society: glossary of terms for thoracic imaging, Radiology, 246, 697, 10.1148/radiol.2462070712

Godoy, 2009, Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management, Radiology, 253, 606, 10.1148/radiol.2533090179

Lee, 2009, Usefulness of concurrent reading using thin-section and thick-section CT images in subcentimetre solitary pulmonary nodules, Clin Radiol, 64, 127, 10.1016/j.crad.2008.09.003

Takashima, 2003, Small solitary pulmonary nodules (< or =1 cm) detected at population-based CT screening for lung cancer: reliable high-resolution CT features of benign lesions, AJR Am J Roentgenol, 180, 955, 10.2214/ajr.180.4.1800955

Ishikawa, 2005, Ultrasmall pulmonary opacities on multidetector-row high-resolution computed tomography: a prospective radiologic-pathologic examination, J Comput Assist Tomogr, 29, 621, 10.1097/01.rct.0000172672.09564.8c

Kishi, 2004, Small lung tumors with the size of 1cm or less in diameter: clinical, radiological, and histopathological characteristics, Lung Cancer, 44, 43, 10.1016/j.lungcan.2003.09.024

Kim, 2007, Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons, Radiology, 245, 267, 10.1148/radiol.2451061682

Kim, 2009, Clinical, pathological and thin-section CT features of persistent multiple ground-glass opacity nodules: comparison with solitary ground-glass opacity nodule, Lung Cancer, 64, 171, 10.1016/j.lungcan.2008.08.002

Ikeda, 2007, Differential diagnosis of ground-glass opacity nodules: CT number analysis by three-dimensional computerized quantification, Chest, 132, 984, 10.1378/chest.07-0793

Choi, 2000, CT bronchus sign in malignant solitary pulmonary lesions: value in the prediction of cell type, Eur Radiol, 10, 1304, 10.1007/s003300000315

Takashima, 2003, CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern, AJR Am J Roentgenol, 180, 817, 10.2214/ajr.180.3.1800817

Gould, 2007, Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition), Chest, 132, 108S, 10.1378/chest.07-1353

Nakazono, 2005, Subtypes of peripheral adenocarcinoma of the lung: differentiation by thin-section CT, Eur Radiol, 15, 1563, 10.1007/s00330-004-2595-7

Zwirewich, 1991, Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation, Radiology, 179, 469, 10.1148/radiology.179.2.2014294

Yang, 2001, High-resolution CT analysis of small peripheral lung adenocarcinomas revealed on screening helical CT, AJR Am J Roentgenol, 176, 1399, 10.2214/ajr.176.6.1761399

Tateishi, 2005, Prediction of lung adenocarcinoma without vessel invasion: a CT scan volumetric analysis, Chest, 128, 3276, 10.1378/chest.128.5.3276

Kojima, 2010, Correlations of thin-section computed tomographic, histopathological, and clinical findings of adenocarcinoma with a bubblelike appearance, J Comput Assist Tomogr, 34, 413, 10.1097/RCT.0b013e3181d275b6

Yoshino, 2000, Pleural retraction and intra-tumoral air-bronchogram as prognostic factors for stage I pulmonary adenocarcinoma following complete resection, Int Surg, 85, 105

Kondo, 2002, Radiologic-prognostic correlation in patients with small pulmonary adenocarcinomas, Lung Cancer, 36, 49, 10.1016/S0169-5002(01)00448-2

Sakao, 2004, Predictive factors for survival in surgically resected clinical IA peripheral adenocarcinoma of the lung, Ann Thorac Surg, 77, 1157, 10.1016/j.athoracsur.2003.09.055

Kuriyama, 1999, Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma of the lung, AJR Am J Roentgenol, 173, 465, 10.2214/ajr.173.2.10430155

Castro, 2001, Prognostic significance of percentage of bronchioloalveolar pattern in adenocarcinomas of the lung, Ann Diagn Pathol, 5, 274, 10.1053/adpa.2001.27915

Hashizume, 2008, Prognostic significance of thin-section CT scan findings in small-sized lung adenocarcinoma, Chest, 133, 441, 10.1378/chest.07-1533

Dong, 2002, Computed tomographic image comparison between mediastinal and lung windows provides possible prognostic information in patients with small peripheral lung adenocarcinoma, J Thorac Cardiovasc Surg, 124, 1014, 10.1067/mtc.2002.125647

Matsuguma, 2002, Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: a predictor of lymph node metastasis, J Thorac Cardiovasc Surg, 124, 278, 10.1067/mtc.2002.122298

Ohde, 2003, The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma, Lung Cancer, 42, 303, 10.1016/j.lungcan.2003.07.001

Okada, 2004, Correlation between computed tomographic findings, bronchioloalveolar carcinoma component, and biologic behavior of small-sized lung adenocarcinomas, J Thorac Cardiovasc Surg, 127, 857, 10.1016/j.jtcvs.2003.08.048

Sakao, 2004, Lung adenocarcinoma can be subtyped according to tumor dimension by computed tomography mediastinal-window setting. Additional size criteria for clinical T1 adenocarcinoma, Eur J Cardiothorac Surg, 26, 1211, 10.1016/j.ejcts.2004.08.021

Seki, 2008, Lung cancer with localized ground-glass attenuation represents early-stage adenocarcinoma in nonsmokers, J Thorac Oncol, 3, 483, 10.1097/JTO.0b013e31816a4994

Takashima, 2003, High-resolution CT features: prognostic significance in peripheral lung adenocarcinoma with bronchioloalveolar carcinoma components, Respiration, 70, 36, 10.1159/000068410

Nishio, 2007, The ratio of the maximum high attenuation area dimension to the maximum tumor dimension may be an index of the presence of lymph node metastasis in lung adenocarcinomas 3 cm or smaller on high-resolution computed tomography, J Thorac Oncol, 2, 29, 10.1016/S1556-0864(15)30014-9

Shim, 2009, Prognostic significance of visceral pleural invasion in the forthcoming (seventh) edition of TNM classification for lung cancer, Lung Cancer, 65, 161, 10.1016/j.lungcan.2008.11.008

Ikehara M, Saito H, Kondo T, et al. Comparison of thin-section CT and pathological findings in small solid-density type pulmonary adenocarcinoma: prognostic factors from CT findings. Eur J Radiol. In press.

Gaeta, 2002, CT and MRI findings of mucin-containing tumors and pseudotumors of the thorax: pictorial review, Eur Radiol, 12, 181, 10.1007/s003300100934

Nakata, 2003, Prospective study of thoracoscopic limited resection for ground-glass opacity selected by computed tomography, Ann Thorac Surg, 75, 1601, 10.1016/S0003-4975(02)04815-4

Takashima, 2002, Prognostic significance of high-resolution CT findings in small peripheral adenocarcinoma of the lung: a retrospective study on 64 patients, Lung Cancer, 36, 289, 10.1016/S0169-5002(01)00489-5

Hiramatsu, 2008, Pulmonary ground-glass opacity (GGO) lesions-large size and a history of lung cancer are risk factors for growth, J Thorac Oncol, 3, 1245, 10.1097/JTO.0b013e318189f526

Austin, 2008, Carcinoma of the lung and metastatic disease of the central nervous system, Am J Respir Crit Care Med, 178, 1090, 10.1164/ajrccm.178.10.1090

Mujoomdar, 2007, Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases, Radiology, 242, 882, 10.1148/radiol.2423051707

MacMahon, 2005, Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society, Radiology, 237, 395, 10.1148/radiol.2372041887

Eisenberg, 2010, Compliance with Fleischner Society guidelines for management of small lung nodules: a survey of 834 radiologists, Radiology, 255, 218, 10.1148/radiol.09091556

MacMahon, 2010, Compliance with Fleischner Society guidelines for management of lung nodules: lessons and opportunities, Radiology, 255, 14, 10.1148/radiol.10092382

Zhao, 2009, Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer, Radiology, 252, 263, 10.1148/radiol.2522081593

Ravenel, 2008, Pulmonary nodule volume: effects of reconstruction parameters on automated measurements—a phantom study, Radiology, 247, 400, 10.1148/radiol.2472070868

Jennings, 2004, Lung tumor growth: assessment with CT–comparison of diameter and cross-sectional area with volume measurements, Radiology, 231, 866, 10.1148/radiol.2313030715

Winer-Muram, 2003, Effect of varying CT section width on volumetric measurement of lung tumors and application of compensatory equations, Radiology, 229, 184, 10.1148/radiol.2291020859

Yankelevitz, 2000, Small pulmonary nodules: volumetrically determined growth rates based on CT evaluation, Radiology, 217, 251, 10.1148/radiology.217.1.r00oc33251

de Hoop, 2010, Pulmonary ground-glass nodules: increase in mass as an early indicator of growth, Radiology, 255, 199, 10.1148/radiol.09090571

Nakata, 2004, Surgical treatments for multiple primary adenocarcinoma of the lung, Ann Thorac Surg, 78, 1194, 10.1016/j.athoracsur.2004.03.102

Zwirewich, 1990, Multicentric adenocarcinoma of the lung: CT-pathologic correlation, Radiology, 176, 185, 10.1148/radiology.176.1.2162069

Park, 2008, Pulmonary nodular ground-glass opacities in patients with extrapulmonary cancers: what is their clinical significance and how can we determine whether they are malignant or benign lesions?, Chest, 133, 1402, 10.1378/chest.07-2568

Okada, 2007, Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas, J Thorac Cardiovasc Surg, 133, 1448, 10.1016/j.jtcvs.2007.02.023

Higashi, 1998, Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma, J Nucl Med, 39, 1016

Higashi, 2000, FDG PET measurement of the proliferative potential of non-small cell lung cancer, J Nucl Med, 41, 85

Higashi, 2000, FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features, Nucl Med Commun, 21, 707, 10.1097/00006231-200008000-00002

Ohtsuka, 2006, Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma, Cancer, 107, 2468, 10.1002/cncr.22268

Raz, 2006, Tumor fluoro-2-deoxy-D-glucose avidity on positron emission tomographic scan predicts mortality in patients with early-stage pure and mixed bronchioloalveolar carcinoma, J Thorac Cardiovasc Surg, 132, 1189, 10.1016/j.jtcvs.2006.06.033

Sagawa, 2006, Fluorodeoxyglucose uptake correlates with the growth pattern of small peripheral pulmonary adenocarcinoma, Surg Today, 36, 230, 10.1007/s00595-005-3123-3

Pastorino, 2009, Fluorodeoxyglucose uptake measured by positron emission tomography and standardized uptake value predicts long-term survival of CT screening detected lung cancer in heavy smokers, J Thorac Oncol, 4, 1352, 10.1097/JTO.0b013e3181bbf1dc

Nakayama, 2010, Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: a multicenter study, Cancer, 116, 3170, 10.1002/cncr.25244

Um, 2009, Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer, J Thorac Oncol, 4, 1331, 10.1097/JTO.0b013e3181b6be3e

Berghmans, 2008, J Thorac Oncol, 3, 6, 10.1097/JTO.0b013e31815e6d6b

Birchard, 2009, Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival, Cancer, 115, 581, 10.1002/cncr.24060

Sohn, 2008, [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung, Clin Cancer Res, 14, 7423, 10.1158/1078-0432.CCR-08-0312

Cloran, 2010, Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity, Lung Cancer, 68, 66, 10.1016/j.lungcan.2009.05.013

Ohno, 2004, Dynamic MR imaging: value of differentiating subtypes of peripheral small adenocarcinoma of the lung, Eur J Radiol, 52, 144, 10.1016/j.ejrad.2004.01.015

van Klaveren, 2009, Management of lung nodules detected by volume CT scanning, N Engl J Med, 361, 2221, 10.1056/NEJMoa0906085

Oda, 2010, Computer-aided volumetry of pulmonary nodules exhibiting ground-glass opacity at MDCT, AJR Am J Roentgenol, 194, 398, 10.2214/AJR.09.2583

Henschke, 1999, Early Lung Cancer Action Project: overall design and findings from baseline screening, Lancet, 354, 99, 10.1016/S0140-6736(99)06093-6

Henschke, 2001, Early lung cancer action project: initial findings on repeat screenings, Cancer, 92, 153, 10.1002/1097-0142(20010701)92:1<153::AID-CNCR1303>3.0.CO;2-S

Lindell, 2007, Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers, Radiology, 242, 555, 10.1148/radiol.2422052090

Hasegawa, 2000, Growth rate of small lung cancers detected on mass CT screening, Br J Radiol, 73, 1252, 10.1259/bjr.73.876.11205667

Henschke, 2006, Survival of patients with stage I lung cancer detected on CT screening, N Engl J Med, 355, 1763, 10.1056/NEJMoa060476

Kakinuma, 2004, Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer, J Comput Assist Tomogr, 28, 17, 10.1097/00004728-200401000-00003

Sone, 2007, Long-term follow-up study of a population-based 1996–1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography, Lung Cancer, 58, 329, 10.1016/j.lungcan.2007.06.022

Pelosi, 2008, Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study, Lung Cancer, 62, 202, 10.1016/j.lungcan.2008.03.012

Wang, 2000, Rapidly growing small peripheral lung cancers detected by screening CT: correlation between radiological appearance and pathological features, Br J Radiol, 73, 930, 10.1259/bjr.73.873.11064644

Infante, 2009, A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial, Am J Respir Crit Care Med, 180, 445, 10.1164/rccm.200901-0076OC

Bepler, 2009, Are we coming full circle for lung cancer screening a second time?, Am J Respir Crit Care Med, 180, 384, 10.1164/rccm.200906-0977ED

McMahon, 2008, Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study, Radiology, 248, 278, 10.1148/radiol.2481071446

McMahon, 2008, Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period, Cancer, 113, 3440, 10.1002/cncr.23962

Gatsonis, 2011, The National Lung Screening Trial: overview and study design, Radiology, 258, 243, 10.1148/radiol.10091808

Park, 2009, EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: investigation of significantly related factors on CT, FDG-PET, and histopathology, Lung Cancer, 64, 179, 10.1016/j.lungcan.2008.08.003

Yano, 2006, Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma, J Thorac Oncol, 1, 413, 10.1016/S1556-0864(15)31604-X

Chantranuwat, 2005, Histopathologic characteristics of pulmonary adenocarcinomas with and without EGFR mutation, J Med Assoc Thai, 88, S322

Huang, 2010, Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma, Med Oncol, 27, 9, 10.1007/s12032-008-9160-1

Watanabe, 2006, [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas, Jpn J Clin Oncol, 36, 403, 10.1093/jjco/hyl043

Vesselle, 2008, Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index, J Thorac Oncol, 3, 971, 10.1097/JTO.0b013e31818307a7

Schuchert, 2007, Anatomic segmentectomy in the treatment of stage I non-small cell lung cancer, Ann Thorac Surg, 84, 926, 10.1016/j.athoracsur.2007.05.007

Shapiro, 2009, Thoracoscopic segmentectomy compares favorably with thoracoscopic lobectomy for patients with small stage I lung cancer, J Thorac Cardiovasc Surg, 137, 1388, 10.1016/j.jtcvs.2009.02.009

Yan, 2009, Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer, J Clin Oncol, 27, 2553, 10.1200/JCO.2008.18.2733

Watanabe, 2005, Intentional limited resection for small peripheral lung cancer based on intraoperative pathologic exploration, Jpn J Thorac Cardiovasc Surg, 53, 29, 10.1007/s11748-005-1005-7

Higashiyama, 2003, Intraoperative lavage cytologic analysis of surgical margins in patients undergoing limited surgery for lung cancer, J Thorac Cardiovasc Surg, 125, 101, 10.1067/mtc.2003.92

Utsumi, 2010, Optimal sampling methods for margin cytology examination following lung excision, Interact Cardiovasc Thorac Surg, 10, 434, 10.1510/icvts.2009.212142

Asamura, 2003, A clinicopathological study of resected subcentimeter lung cancers: a favorable prognosis for ground glass opacity lesions, Ann Thorac Surg, 76, 1016, 10.1016/S0003-4975(03)00835-X

Ginsberg, 1995, Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group, Ann Thorac Surg, 60, 615, 10.1016/0003-4975(95)00537-U

Miller, 2002, Surgical treatment of non-small cell lung cancer 1 cm or less in diameter, Ann Thorac Surg, 73, 1545, 10.1016/S0003-4975(02)03525-7

Rami-Porta, 2005, Complete resection in lung cancer surgery: proposed definition, Lung Cancer, 49, 25, 10.1016/j.lungcan.2005.01.001

Ishiguro, 2010, Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score, J Thorac Cardiovasc Surg, 139, 1001, 10.1016/j.jtcvs.2009.07.024

Darling GE, Allen MS, Landreneau RJ, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the ACOSOG Z0030 Trial. J Thorac Cardiovasc Surg. In press.

Nomori, 2006, Omission of mediastinal lymph node dissection in lung cancer: its techniques and diagnostic procedures, Ann Thorac Cardiovasc Surg, 12, 83

Finley, 2010, Predictors of outcomes after surgical treatment of synchronous primary lung cancers, J Thorac Oncol, 5, 197, 10.1097/JTO.0b013e3181c814c5

Hayes, 2009, Breast, 347

Yatabe, 2007, Epidermal growth factor receptor mutations in lung cancers, Pathol Int, 57, 233, 10.1111/j.1440-1827.2007.02098.x

Holst, 1998, Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease, Am J Surg Pathol, 22, 1343, 10.1097/00000478-199811000-00004

Furak, 2003, Bronchioloalveolar lung cancer: occurrence, surgical treatment and survival, Eur J Cardiothorac Surg, 23, 818, 10.1016/S1010-7940(03)00084-8

Clayton, 1988, The spectrum and significance of bronchioloalveolar carcinomas, Pathol Annu, 23, 361

Lau, 2002, Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases, Mod Pathol, 15, 538, 10.1038/modpathol.3880560

Sarantopoulos, 2004, Immunohistochemical analysis of lung carcinomas with pure or partial bronchioloalveolar differentiation, Arch Pathol Lab Med, 128, 406, 10.5858/2004-128-406-IAOLCW

Simsir, 2004, Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens, Am J Clin Pathol, 121, 350, 10.1309/CM20WA20RW3T600L

Sonobe, 2005, Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma, Br J Cancer, 93, 355, 10.1038/sj.bjc.6602707

Ohtsuka, 2006, Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma, J Thorac Oncol, 1, 787, 10.1016/S1556-0864(15)30407-X

Sonobe, 2006, Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain, J Mol Diagn, 8, 351, 10.2353/jmoldx.2006.050132

Ninomiya, 2009, Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type, Lung Cancer, 63, 235, 10.1016/j.lungcan.2008.04.017

Stenhouse, 2004, Thyroid transcription factor 1 in pulmonary adenocarcinoma, J Clin Pathol, 57, 383, 10.1136/jcp.2003.007138

Shrestha, 1998, Immunohistochemical, ultrastructural and molecular study of well differentiated adenocarcinomas of the lung predominantly composed of goblet cells, Lung Cancer, 22, 103, 10.1016/S0169-5002(98)00052-X

Yatabe, 2004, CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas, J Pathol, 203, 645, 10.1002/path.1566